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Morphine effects on mouse brains <p>Global transcriptional analysis of mouse striata following acute and chronic exposure to morphine reveals multiple physiological fac- tors which may affect opioid-related phenotypes and implicates a number of gene networks, including glucocorticoid receptor regulated  genes, in the response to this opioid.</p>
Abstract
Background: Chronic opiate use produces molecular and cellular adaptations in the nervous
system that lead to tolerance, physical dependence, and addiction. Genome-wide comparison of
morphine-induced changes in brain transcription of mouse strains with different opioid-related
phenotypes provides an opportunity to discover the relationship between gene expression and
behavioral response to the drug.
Results: Here, we analyzed the effects of single and repeated morphine administrations in selected
inbred mouse strains (129P3/J, DBA/2J, C57BL/6J, and SWR/J). Using microarray-based gene
expression profiling in striatum, we found 618 (false discovery rate < 1%) morphine-responsive
transcripts. Through ontologic classification, we linked particular sets of genes to biologic functions,
including metabolism, transmission of nerve impulse, and cell-cell signaling. We identified numerous
novel morphine-regulated genes (for instance, Olig2 and Camk1g), and a number of transcripts with
strain-specific changes in expression (for instance, Hspa1a and Fzd2). Moreover, transcriptional
activation of a pattern of co-expressed genes (for instance, Tsc22d3 and Nfkbia) was identified as
being mediated via the glucocorticoid receptor (GR). Further studies revealed that blockade of the
GR altered morphine-induced locomotor activity and development of physical dependence.
Conclusion: Our results indicate that there are differences between strains in the magnitude of
transcriptional response to acute morphine treatment and in the degree of tolerance in gene
expression observed after chronic morphine treatment. Using whole-genome transcriptional
analysis of morphine effects in the striatum, we were able to reveal multiple physiological factors
that may influence opioid-related phenotypes and to relate particular gene networks to this
complex trait. The results also suggest the possible involvement of GR-regulated genes in mediating
behavioral response to morphine.
Background
Opioids are considered to be among the most potent drugs for
relieving severe chronic pain. Long-term morphine treatment
is undesirable because of the development of tolerance to its
analgesic effects and physical dependence. On the other
hand, prolonged abuse of opiates leads to drug addiction - a
chronic, relapsing disorder with a complex mechanism. Accu-
mulating evidence is converging to suggest that formation of
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opioid addiction involves changes in synaptic structure and
neuronal plasticity [1]. These long-lasting neuroadaptations
probably include compound changes in gene expression in
the mesocorticolimbic system of the brain [2]. The major sub-
strates of the molecular and cellular mechanisms of opioid
addiction are suggested to be the dorsal and ventral striatum.
Morphine administration enhances the release of dopamine
in both the dorsal striatum and nucleus accumbens [3]. It is
well established that the nucleus accumbens, a ventral subre-
gion that receives dopaminergic projections from the ventral
tegmental area, is related to the reward properties of opioids
[4]. The dorsal part of the striatum is a brain region that is
implicated in habit learning, which is a fundamental compo-
nent of addiction [5].
It is well known that drugs of abuse stimulate the transcrip-
tion of numerous genes in several brain regions [6,7]. Moreo-
ver, a significant contribution of genetic factors to
vulnerability to the addictive action of opiates and other
addictive drugs is well established [8]. Several other effects of
opioid action, for example analgesia and hypothermia, are
also likely to be determined by combinations of genetic fac-
tors [9]. In contrast, the influence of genotype on genomic
response to opioids and the association between changes in
gene expression and development of the rewarding and
addictive effects are poorly characterized. Inbred strains of
mice with well described phenotypes provide valuable models
in which to analyze interactions between genetic background,
and behavioral and transcriptional responses to the drug.
To separate the relationship between the different effects of
morphine and the gene expression profiles in the striatum, we
compared responses to acute and chronic drug treatment
across four mouse strains with extreme opioid-related pheno-
types (C57BL/6J, DBA/2J, 129P3/J, and SWR/J). Two com-
monly used inbred strains of mice, C57BL/6J and DBA/2J,
exhibit remarkable differences in morphine-induced locomo-
tor activation and conditional place preference [10,11]. Com-
pared with the other strains, C57BL/6J mice were found to
have the greatest preference for oral self-administered mor-
phine [12]. Furthermore, the 129P3/J strain failed to develop
physical dependence and tolerance, whereas extraordinary
sensitivity to opioid withdrawal was observed in SWR/J mice
[13].
Our prior comparison of gene expression profiles of naïve ani-
mals from the selected inbred mouse strains indicated diver-
sity at the level of several hundreds of transcripts in the
striatum [14]. Here, we use microarray technology to obtain a
profile of genes that are regulated by acute and chronic mor-
phine in the striatum of the four mouse strains. Our ultimate
goal is to link particular genes, regulatory elements, and spe-
cific signaling pathways with opioid-related traits. To this
end, we have combined gene expression profiling with bioin-
formatic approaches and behavioral testing. The results pre-
sented here identify several novel morphine-responsive genes
that may modulate the molecular as well as behavioral
response to morphine and may contribute to development of
morphine addiction.
Results
Microarray analysis
A microarray experiment was designed to determine the
impact of genetic background on the transcriptional effects of
morphine in striatum. Twelve experimental groups were
compared to analyze the transcriptional response to acute
and chronic morphine among the four inbred strains of mice
(Figure 1). Three biologic replicates of the microarray were
prepared for each experimental group. The quality of micro-
arrays was carefully checked to ensure that hybridization of
the samples to the arrays was comparable across the dataset
composed of 36 microarrays (see Materials and methods,
below). Correlation coefficients of raw microarray results
within the strains (129P3/J: 0.986 to 0.988; C57BL/6J: 0.977
to 0.993; DBA/2J: 0.979 to 0.99; and SWR/J: 0.983 to
0.987) and within the experimental groups (control: 0.977 to
0.987; acute: 0.988 to 0.993; and chronic: 0.981 to 0.987)
were very high. The microarray data reported in this manu-
script are publicly available at the Gene Expression Omnibus
database under accession number GSE7762 [15].
Signals from 21,467 probe sets were detected reproducibly on
the microarrays, representing 46% of all probe sets on the
microarray (23,633 were filtered out). Genes annotated to
these probe sets were considered to be expressed in the exam-
ined brain tissue. The list of detected probe sets was used for
further analyses. Main factors (strain and treatment), as well
as interaction, were calculated by using multivariate analysis
of variance (MANOVA).
Protocol of morphine administration Figure 1
Protocol of morphine administration. Acutely treated mice (n = 9) were 
injected with a single dose of morphine (20 mg/kg, subcutaneously). 
Chronically treated animals (n = 9) were injected with increasing doses of 
morphine for 5 days (10, 20, and 40 mg/kg, subcutaneously; see Materials 
and methods). Control (n = 9) and acute morphine groups received 
injections of saline in the same time schedule as the chronic group 
received morphine. Animals were killed by decapitation 4 hours after the 
last injection. The time point used for tissue collection and gene 
expression analysis is indicated by the red arrow.
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Strain differences in gene expression profile
The influence of genetic background on gene expression level
was estimated. Our previously presented comparison of basal
gene expression profiles between C57BL/6J, DBA/2J, 129P3/
J, and SWR/J strains identified more than 1,000 transcripts
with a different level of mRNA [14]. At present, using similar
statistical criteria as previously (false discovery rate [FDR] <
1%, rank > 3), we identified 3,457 probe sets (corresponded to
2,870 different transcripts) with significant inter-strain dif-
ferences (Additional data file 1). Such a large disparity in the
mouse striatal transcriptome was estimated by comparing
nine array replicates prepared per strain from all of the treat-
ment groups. More than half of the identified probe sets
exhibited markedly significant results (1,735 with rank > 7;
see Materials and methods, below, for details). To estimate
the quantitative magnitude of the differences between tran-
scriptional profiles, we compared the relative expression level
measured for each strain with the mean level of expression
from the four strains. Only about 100 probe sets in each
strain, from the total of 3,457, were recognized as exhibiting a
more than twofold difference over mean value (Table 1).
However, levels of expression of about 1,000 genes in each
strain were found to differ by at least 1.2-fold. About 25%
transcripts had higher expression and about 75% had lower
expression compared with the other three strains. The
observed distribution of differences was similar across the
four inbred strains, with the modest exception for C57BL/6J
mice. In this strain, similar amounts of transcripts were over
and under the mean value.
The contribution of strain or treatment factors to the varia-
tion in expression of each gene was described by the portion
of multiple regression R2 attributable to strain and morphine
treatment as the main effects. Average R2 value was greater
for strain effects than for morphine treatment effects. Almost
50-fold more transcripts exhibit R2 above 0.6 for strain effects
(2,080) than for treatment effects (43).
Morphine effects on striatal gene transcription
Morphine treatment altered the expression of 618 transcripts
covered by 661 probe sets (FDR < 1%, rank > 3; Additional
data file 1). A group of transcripts (56 probe sets) with a high
level of significance (rank > 7) was used in hierarchical clus-
tering analysis to present example patterns of genes with
altered expression (Figure 2). To validate the results obtained
by microarrays, quantitative real-time reverse transcription
polymerase chain reaction (qPCR) experiments were per-
formed using aliquots of the nonpooled total RNA. From the
list of the most significant 56 probe sets, novel morphine-
responsive genes with putative neuronal function were
selected. The treatment factor in MANOVA was significant
for all of the transcripts examined by qPCR. Equal upregula-
tion (about 1.5-fold to 2-fold) of mRNAs for serum/glucocor-
ticoid regulated kinase 3 (Sgk3) and calcium/calmodulin-
dependent protein kinase I gamma (Camk1g) was observed
after acute and chronic morphine exposure in all four strains
of mice. Greater than twofold induction of zinc finger and
BTB domain containing 16 (Zbtb16/Zfp145) mRNA after
acute treatment was confirmed, and this induction was lower
after prolonged administration. Furthermore, an increase in
the abundance of the frizzled homolog 2 (Fzd2) transcript
after chronic morphine exposure was detected in all four
strains, with the greatest fold change in C57BL/6J mice (Fig-
ure 2).
Acute and chronic effects of morphine were compared in
terms of fold change in the microarray findings (Additional
data file 2). The greatest induction of gene expression was
observed after acute administration, and this response
appeared to be tolerated during further injections of mor-
phine. A total of 181 transcripts exhibited more than 1.2-fold
(38 with >1.5-fold) greater expression after acute morphine
exposure compared with control groups. In contrast, only 76
(13 with >1.5-fold) were upregulated after chronic treatment
(Table 2). Moreover, transcription of about three-quarters of
these genes (53) was also activated by acute morphine. Acute
morphine reduced the expression of 69 transcripts, and for 29
of them these changes were also observed after repeated
injections. Chronic morphine treatment decreased mRNA
level of 145 (nine by >1.5-fold) genes in total (Figure 3b).
To identify functional associations between genes with
expression that was altered by morphine, a list of probe sets
with more than 1.2-fold change over the control group was
analyzed by Gene Ontology (GO). Detailed description of the
Table 1
Summary of genotype-dependent differences in striatal gene expression profile between mouse strains
Fold change of mean mRNA levela 129P3/J strain C57BL/6J strain DBA/2J strain SWR/J strain
>1.2 906 (+295)b 925 (+511) 888 (+277) 924 (+391)
>1.5 261 (+50) 230 (+108) 288 (+53) 256 (+60)
>2 99 (+9) 68 (+29) 111 (+14) 89 (+9)
>3 43 20 (+6) 48 (+5) 36
The mouse strains evaluated were 129P3/J, C57BL/6J, DBA/2J, and SWR/J. aFold change over mean mRNA level from all four strains for 3,457 
significantly different probe sets. Relative expression levels were computed from MBEI perfect match/mismatch (PM/MM) data. bTotal numbers of 
probe sets are presented. In addition, numbers of transcripts with increased level comparing to mean are included in parentheses.R128.4 Genome Biology 2007,     Volume 8, Issue 6, Article R128       Korostynski et al. http://genomebiology.com/2007/8/6/R128
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results of GO classification, together with gene names, is
included in Additional data file 3. Among the most abundant
group of genes (upregulated after acute morphine), func-
tional patterns of transcripts connected with response to abi-
o t i c  ( G O :  0 0 0 9 6 2 8 ;  1 3  t r a n s c r i p t s ;  P  = 0.0001) and
temperature (GO: 0009266; four transcripts; P  = 0.004)
stimuli were identified as being over-represented. Also, genes
associated with negative regulation of cellular processes (GO:
0048532; 17 transcripts; P = 0.001) and regulation of apopto-
sis (GO: 0042981; ten transcripts; P = 0.005) were over-rep-
resented, including Sgk3 and Zbtb16 transcripts.
In contrast, acute morphine caused the downregulation of
genes involved in nervous system development (GO:
0007399; eight transcripts; P = 0.003). At least two tran-
scriptional regulators involved in oligodendrogenesis,
namely oligodendrocyte transcription factor 2 (Olig2) and
GLI-Kruppel family member (Gli3), were identified in this
group. Downregulation was also observed for genes associ-
ated with cell-cell communication (GO: 0007154; 17 tran-
scripts; P = 0.008), including the synphilin (Sncaip) protein,
which is involved in synaptic function.
Repeated opioid administration maintained an increased
mRNA level of genes related to negative regulation of
Gene expression changes induced by morphine treatment in the striatum of the four inbred strains of mice Figure 2
Gene expression changes induced by morphine treatment in the striatum of the four inbred strains of mice. The four strains were C57BL/6J, DBA/2J, 
SWR/J, and 129P3/J. (a) Clustering image of genes whose expression was the most significantly altered, according to microarray analysis (SAL, control 
group; MOR, acute [ACU] and chronic [CHR] morphine groups). Colored rectangles represent expression levels of the gene indicated by the probe set 
on the left. Intensity of the color is proportional to the fold change, as indicated on the bar below the cluster image. Hierarchical clustering was performed 
with the dChip software using Euclidean distance and average linkage method. (b) Validation of morphine-induced regulation of expression of the selected 
genes by quantitative real-time reverse transcription polymerase chain reaction (qPCR). Results are presented as fold change over control group with 
standard error (n = 6 to 9). Significant main effects from multivariate analysis of variance for morphine treatment (***P < 0.001) and interaction ($P < 0.05) 
are indicated. Difference between morphine-treated and control groups was analyzed using Bonferroni post hoc test (#P < 0.05).
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apoptosis (GO: 0043066; five transcripts; P = 0.002). The
decrease in cell-cell signaling genes (GO: 0007267; seven
transcripts; P = 0.005), including those encoding gap junc-
tion membrane proteins α12 and β1 (Gja12 and Gjb1), was
also detected. In addition, chronic treatment decreased the
expression of several genes that are involved in nucleosome
assembly (GO:0006334; five transcripts; P = 0.001). This
functional category contains several histone genes, for
instance H1c and H2bp.
Strain differences in transcriptional response to 
morphine
Comparison of changes in gene expression profile across the
inbred mouse strains with diverse opioid-related phenotypes
provides the possibility to find direct associations between
transcriptional and behavioral response to the drug. From the
list of genes responsive to morphine (661 probe sets), 178
exhibited different levels of mRNA abundance also at basal
conditions (Figure 3a). Furthermore, evaluation of the inter-
action between two main factors (strain and treatment) in
MANOVA analysis identified 48 probe sets (rank > 3) for
genes with transcriptional difference between the strains in
response to morphine. Significant interaction was detected
for Sgk, Nfkbia, and Hspa1b, for example (Additional data
file 1).
Comparison of the magnitude of inter-strain differences in
the level of mRNA across morphine treatments was charac-
terized by fold change (Table 2). Lists of probe sets with more
than 1.2-fold and 1.5-fold change in signal for each experi-
mental group were obtained. In general, transcription was
mostly increased after a single injection of morphine in all of
the strains, whereas repeated administration caused a
decrease in the expression levels of a large number of genes.
The transcriptional response to acute morphine was the
strongest in the DBA/2J strain, whereas chronic morphine
affected most the C57BL/6J mice. Furthermore, to character-
ize the transcriptional representation of biologic processes
initiated by morphine in the striatum, ontologic analysis of
Table 2
Summary of morphine-induced changes in gene expression level in the four inbred strains
Treatment Fold change over control All of the four strains 129P3/J strain C57BL/6J strain DBA/2J strain SWR/J strain
Acute upregulation >1.2a 181 179 106 313 255
>1.5 38 33 39 81 42
Acute downregulation >1.2 69 44 108 68 67
>1.5 6 4 25 25 14
Chronic upregulation >1.2 76 90 116 59 63
>1.5 13 17 38 8 10
Chronic downregulation >1.2 145 83 278 98 141
>1.5 9 9 61 10 12
The mouse strains evaluated were 129P3/J, C57BL/6J, DBA/2J, and SWR/J. aAnalysis was performed for the group of transcripts significantly changed 
after morphine treatment. Relative expression levels for 661 probe sets were computed using MBEI perfect match/mismatch (PM/MM) data.
Comparison of the number of genes with expression altered by genotype  and morphine treatment Figure 3
Comparison of the number of genes with expression altered by genotype 
and morphine treatment. (a) In all, 178 probe sets were shared between 
genes with different levels across the four inbred strains (red circle) and 
morphine-responsive genes (yellow circle). (b) Approximately three-
quarters of genes upregulated by chronic treatment (green circles) were 
also altered by acute morphine treatment (blue circles). On the other 
hand, 29 genes with a decreased level of mRNA after acute treatment 
were found in the list of 145 downregulated genes after repeated 
morphine administration. The list of probe sets with greater than 1.2-fold 
change over control was analyzed.
Up-regulated Down-regulated
Strain
Morphine
(a)
(b)R128.6 Genome Biology 2007,     Volume 8, Issue 6, Article R128       Korostynski et al. http://genomebiology.com/2007/8/6/R128
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genes with altered expression was performed (Table 3). Func-
tional annotation was done in each strain on a list of tran-
scripts with a fold change greater than 1.2 (Additional data
file 3).
In the C57BL/6J mice, a single morphine injection induced
the transcription of genes classified under several GO terms
associated with apoptosis (GO: 0042981, GO: 0006915, GO:
0043066, GO: 0043066, GO: 0043068, and GO: 0006916),
for example regulation of apoptosis (GO: 0042981; 11 tran-
scripts; P = 0.00001). However, the neuronal functions of
genes from this class, such as TSC22 domain family 3
(Tsc22d3/Dsip1/Gilz) or pleckstrin homology domain
containing family F (Plekhf1), are not fully understood and
might not be strictly associated with cell apoptosis. Acute
morphine enhances the transcription of several functional
groups of genes that are related to metabolism, including car-
boxylic acid metabolism (GO: 0019752) in DBA/2J (17 tran-
scripts; P = 0.003) and SWR/J (16 transcripts; P = 0.001), as
well as carbohydrate transport (GO: 0008643) in DBA/2J
(five transcripts; P = 0.005). Proteins with transferase activ-
ity, including methionine adenosyltransferase II, α (Mat2a)
and carnitine O-octanoyltransferase (Crot), were contained
within these groups. Genes involved in glucose transport
(GO: 0015758) were also upregulated in DBA/2J (four tran-
scripts; P = 0.003), C57BL/6J (three transcripts; P = 0.005),
and SWR/J (four transcripts; P = 0.002), including syntaxin
binding proteins 3A (Stxbp3a) and 4 (Stxbp4). Moreover,
morphine induced a group of transcripts involved in response
to temperature stimulus (GO: 0009266). Over-representa-
tion of transcripts associated with response to temperature
was observed after acute injection in DBA/2J (five tran-
scripts; P = 0.002) and SWR/J (four transcripts; P = 0.009),
but also after chronic treatment in DBA/2J (three transcripts;
P = 0.005). For instance, gene transcription of heat shock
proteins Hspa1a and Hspa1b was increased.
Acute injection of morphine downregulated genes that are
involved in nervous system development (GO: 0007399) in
129P3/J (six transcripts; P  = 0.006) and SWR/J (seven
transcripts;  P  = 0.01) mice. However, the function of the
majority of these genes, for example RGM domain family
member A (Rgma) or myocyte enhancer factor 2C (Mef2c), in
the adult brain is poorly characterized. In addition, a similar
group of genes related to neuron differentiation (GO:
0030182) was downregulated in 129P3/J strain (five tran-
scripts; P = 0.002).
Chronic morphine enhances gene expression of factors that
participate in intracellular signaling cascades (GO: 0007242;
12 transcripts; P = 0.01) in 129P3/J mice, including disabled
homolog 1 (Dab1) and protein phosphatase 1 (Ppm1) genes.
Repeated morphine administration caused a reduction in
mRNA abundance of genes that are involved in cellular lipid
metabolism (GO: 0044255; 17 transcripts; P = 0.0002) in the
C57BL/6J strain. Transcripts for very-low-density lipopro-
tein receptor (Vldlr) and sterol-C5-desaturase (Sc5d) were
downregulated. Furthermore, mRNA levels of genes that are
implicated in the transmission of nerve impulse (GO:
0019226) were found to be decreased after prolonged mor-
phine treatment in three of four strains: C57BL/6J (ten tran-
scripts; P = 0.0009), DBA/2J (five transcripts; P = 0.01), and
129P3/J (five transcripts; P = 0.009). Genes encoding synap-
tic receptors neuropeptide Y receptor Y5 (Npy5r), glutamate
receptor ionotropic kainate 2 (Grik2), and GABAa receptor
subunit (Gabrg1) were identified among this group.
Several of the identified genes exhibited strong strain-specific
changes in mRNA abundance. Differences in response were
Table 3
Examples of significantly enriched GO annotation for the list of morphine-responsive genes
Mouse strain Morphine treatment mRNA change Enriched GO annotation (GO ID) Number of 
genes
P Example genes
C57BL/6J Acute +a Regulation of apoptosis (0042981) 11 9.1 × e-06b Tsc22d3, Pmaip1, and Plekhf1
129P3/J Chronic - Nucleosome assembly (0006334) 5 1.7 × e-04 Hist1h1c, Hist1h3b, and Hist1h2bl
C57BL/6J Chronic - Transmission of nerve impulse (0019226) 10 8.6 × e-04 Sncaip, Adora2a, and Npy5r
DBA/2J Acute + Response to abiotic stimulus (0009628) 15 9.8 × e-04 Cryab, Dnajb1, and Cdkn1a
DBA/2J Acute + Response to temperature stimulus (0009266) 5 1.7 × e-03 Hspa8, Hspa1b, and Cryab
C57BL/6J Chronic - Cellular lipid metabolism (0044255) 17 1.95 × e-04 Vldr, Sc5d, and Acsl3
SWR/J Acute + Glucose transport (0015758) 4 2.0 × e-03 Stxbp3a, Stxbp4, and Aps
SWR/J Chronic - Cell communications (0007154) 25 2.3 × e-03 Plcd4, Gjb1, and Utrn
129P3/J Acute - Neuron differentiation (0030182) 5 2.4 × e-03 Olig2, Gli3, and Ablim1
SWR/J Acute + Carboxylic acid metabolism (0019752) 16 1.4 × e-03 Cpt1a, Cpt2, and Crot
C57BL/6J Chronic + Negative regulation of biological process (0048519) 12 7.5 × e-03 Zbtb16, Sgk3, and Adrb1
SWR/J Acute - Nervous system development (0007399) 7 9.9 × e-03 Olig2, Rgma, and Ugt8a
129P3/J Chronic + Intracellular signaling cascade (0007242) 12 1.0 × e-02 Ppm1, Dab1, and Snx24
The complete results of the Gene Ontology (GO) analysis are presented in Additional data file 3. a(+) increased mRNA abundance in response to morphine; (-) decreased 
mRNA level. bStatistical significance of functional over-representation was computed using Fisher's exact test.http://genomebiology.com/2007/8/6/R128 Genome Biology 2007,     Volume 8, Issue 6, Article R128       Korostynski et al. R128.7
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confirmed using the qPCR method. In strain DBA/2J, the
level of heat shock protein 1B (Hspa1b) mRNA was increased
after acute morphine by about 2.5-fold over control. Repeated
treatment significantly reduced this effect in DBA/2J mice.
On the contrary, the C57BL/6J strain exhibited a greater than
threefold induction until after chronic treatment (Figure 4).
Strain-dependent regulation of nuclear factor of kappa light
chain gene enhancer in B-cells inhibitor α (Nfkbia) and dual
specificity phosphatase 14 (Dusp14) transcripts was also ver-
ified by qPCR. Uniquely in the C57BL/6J strain, abundance of
Nfkbia  mRNA was increased almost twofold after acute
morphine compared with control. Dusp14  expression was
a l s o  u p r e g u l a t e d  o n l y  i n  C 5 7BL/6J; a more than twofold
increase was detected after chronic administration (Addi-
tional data file 4). Strain differences in transcriptional
response were also observed for TSC22 domain family 3
(Tsc22d3/Dsip1/Gilz) and CCAAT/enhancer binding protein
C/EBP delta (Cebpd). Both genes were strongly upregulated
after acute morphine in C57BL/6J. However, mRNA level of
Tsc22d3  was also noticeably elevated in the three other
strains (Figure 4c).
Morphine-induced co-regulation of gene transcription Figure 4
Morphine-induced co-regulation of gene transcription. (a) Clusters of genes co-expressed with (1) Hspa1b, (2) Tsc22d3 (Dsip1), and (3) Olig2 after 
morphine treatment (SAL, control group; MOR, acute [ACU] and chronic [CHR] morphine groups). Colored rectangles represent expression levels of the 
gene indicated by the probe set on the left and gene symbol on the right. Intensity of the color is proportional to the fold change as indicated on the bar 
below the cluster image. (b) Network graphs of transcripts co-regulated with (1) Hspa1b, (2) Tsc22d3 (Dsip1), and (3) Olig2 were generated using the 
gene-to-gene correlation tool in WebQTL (Hippocampus Consortium M430v2 Dec05 PDNN). Correlation coefficients for each pair of transcripts are 
indicated beside the line. The Hspa1b gene was represented by three different probe sets on the microarray. (c) Confirmation of morphine induced 
regulation of expression of three selected genes by quantitative real-time reverse transcription polymerase chain reaction (qPCR). Results are presented 
as fold change over control group with standard error (n = 6 to 9). Significant main effects from multivariate analysis of variance for morphine treatment 
(***P < 0.001) and interaction ($$P < 0.01) are indicated. Difference between morphine-treated and control groups was analyzed using Bonferroni post hoc 
test (#P < 0.05).
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Genes co-regulated by morphine treatment
Three genes exhibiting substantial changes in expression
after morphine treatment were selected as potential markers
of biologic processes coordinated at the transcriptional level
(Hspa1b, Tsc22d3, and Olig2). Prediction of co-expression of
genes was verified using gene-to-gene correlation on the
independent dataset. Analyses conducted in a large panel of
BXD recombinant inbred (RI) strains (86) presented an
opportunity to identify associative networks between tran-
scripts [16]. Therefore, we conducted a search for genes with
putative common mechanisms of transcriptional regulation
in response to morphine using trait correlation analysis
implemented in the WebQTL database.
Heat shock protein 70 (Hspa1b) was classified by GO analysis
into functional groups associated with response to
temperature and cellular stress. Thirty-four probe sets exhib-
ited high positive correlations (r > 0.6, n = 86) with Hspa1b
across the BXD RI panel, and four transcripts from this list
were also significantly regulated by morphine. Expression of
Hspa1b was highly correlated with mRNA levels of other heat
shock proteins, namely heat shock protein 72 (Hspa1a) and
heat shock protein 40 (Dnajb1). Inter-strain differences in
response to acute and chronic morphine between C57BL/6J
and DBA/2J were similar for all genes in this group. However,
in the SWR/J mRNA profile, Hspa1b was noticeably different
from  Hspa1a  and  Dnajb1. Interestingly, no changes in
expression of any of these genes were observed in the 129P3/
J strain (Figure 4).
An association between TSC22 domain family 3 (Tsc22d3)
and regulation of apoptosis was identified by GO analysis.
Our further literature search yielded data that implicate the
glucocorticoid receptor (GR) as a potential modulator of
Tsc22d3 transcription [17]. Expression of the Tsc22d3 gene in
the BXD RI panel exhibited a strong positive correlation with
146 transcripts. Unexpectedly, seven genes at the top of this
list (Sgk, Klf15, Fzd2, Gpt2, Rhpn2, and Nt5e), characterized
by a very high level of correlation (r > 0.72, P < 10-16, n = 86)
also had a similar profile after morphine treatment. Moreo-
ver, from the list of 146 probe sets, 17 transcripts exhibited co-
expression with Tsc22d3 in the BXD RI panel and appeared
to be co-regulated after morphine treatment. In addition, this
pattern in transcriptional response to morphine was most
evident in the C57BL/6J strain (Figure 4).
Functional classification implicated oligodendrocyte-specific
bHLH transcription factor 2 (Olig2) in nervous system devel-
opment and neuron differentiation, in particular the develop-
ment of motoneurons and oligodendrocytes. Olig2
expression in the BXD RI panel was positively correlated only
with seven probe sets. This list includes one gene, melanoma
cell adhesion molecule (Mcam), that is regulated by mor-
phine with an analogous profile to Olig2  and decrease in
mRNA level. In addition, Olig1, which had a similar regula-
tion pattern after morphine treatment, was added manually
to this group because functional connections with Olig2 are
well described.
Involvement of glucocorticoid receptor in 
transcriptional response to morphine
The qPCR method was used to evaluate the influence of GR
blockade on acute morphine-induced gene transcription of
selected genes (Tsc22d3, Nfkbia, Zbtb16, Sgk, and Fzd2). All
five genes exhibited marked co-regulation by morphine treat-
ment and co-expression in the BXD RI panel (Figure 4).
Changes in striatal gene expression were evaluated 4 hours
after a single administration of morphine (20 mg/kg, subcu-
taneously). Morphine-induced increases in transcription of
these genes were attenuated by administration of GR receptor
antagonist RU486 30 min before morphine. Dose-dependent
reductions in the increase in gene expression of Tsc22d3 and
Zbtb16  were observed after administration of both tested
doses of RU486 (20 and 40 mg/kg, intraperitoneally). In the
case of Nfkbia, however, morphine-related induction of tran-
scription was significantly attenuated only by the higher dose
(Figure 5). Moreover, acute morphine induction of two other
genes, namely Sgk and Fzd2, also decreased toward the con-
trol level after blockade of GR receptor (20 mg/kg RU486;
data not shown). RU486 treatment did not alter basal mRNA
levels of the selected genes as compared with those in the
vehicle-treated control group. The results of the present study
indicate that GR is involved in the expression of several mor-
phine-responsive genes.
Modulation of behavioral effects of morphine by 
glucocorticoid receptor blockade
The influence of GR blockade on locomotor stimulant effects
of morphine and development of physical dependence was
evaluated in the C57BL/6J strain. Acute morphine (20 mg/
kg, subcutaneously) treatment induced typical hyper-loco-
motion (Figure 6a). Effects of morphine in the GR antagonist
RU486-treated (20 mg/kg) mice were significantly attenu-
ated compared with those in the vehicle-treated animals (P <
0.05). Control groups of animals (treated only with RU486,
saline, or vehicle) did not exhibit locomotor stimulation dur-
ing the experiment; there were also no statistically significant
differences between these groups. RU486 treatment did not
alter basal locomotor activity (Figure 6a).
A single dose of RU486 (20 mg/kg) was administered 30 min
before an injection of morphine (100 mg/kg,
subcutaneously). On the next day animals were injected with
an additional dose of morphine (20 mg/kg, subcutaneously)
followed by injection of naloxone (after 3 hours; 15 mg/kg).
This treatment scheme resulted in robust physical depend-
ence in morphine-treated mice, as revealed by the mean
number of jumps (71.5 ± 9.9 jumps per 15 min). RU486 pre-
treatment significantly suppressed naloxone-precipitated
withdrawal jumping response (21 ± 15.1 jumps per 15 min)
compared with the morphine-treated group (P < 0.05; Figurehttp://genomebiology.com/2007/8/6/R128 Genome Biology 2007,     Volume 8, Issue 6, Article R128       Korostynski et al. R128.9
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Involvement of glucocorticoid receptor in transcriptional response to morphine Figure 5
Involvement of glucocorticoid receptor in transcriptional response to morphine. Inhibition of morphine-induced transcription of selected genes by an 
antagonist of the glucocorticosteroid receptor, namely RU486. Five experimental groups were compared (see Materials and methods): vehicle and acute 
subcutaneous morphine 20 mg/kg (Veh/Mor); morphine preceded by injection of 20 mg/kg RU486 (RU20/Mor); morphine preceded by injection of 40 mg/
kg RU486 (RU40/Mor); and control groups injected with saline and RU486 (RU40/Sal) or saline and vehicle (Veh/Sal). Gene expression in striatum of 
C57BL/6J mice was analyzed 4 hours after morphine treatment. The results of quantitative real-time reverse transcription polymerase chain reaction 
(qPCR) are presented as fold change of control group (Veh/Sal) with standard error. Differences between groups were analyzed by analysis of variance 
ANOVA following Bonferroni multiple comparison correction (n = 5 to 6; **P < 0.01, ***P < 0.001 versus control group; #P < 0.05, ##P < 0.01 versus 
morphine).
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6b). Other signs of opioid withdrawal such as defecation and
urination were also attenuated in RU486-treated mice.
Discussion
Comparison of striatal gene expression profiles of the selected
strains of mice indicated that expression of 2,870 transcripts
was affected by genetic background. The majority of the
detected differences in the mRNA levels were highly statisti-
cally significant but relatively small in the magnitude. A large
degree of disparity between inbred mouse strains in the brain
transcriptome is in accordance with previously published
data [18]. Furthermore, complex strain-specific and region-
specific expression patterns of a number of transcripts were
recently reported [19]. Consequently, differences in mRNA
distribution restricted to subregions or specific cellular popu-
lations in striatum are among the possible explanations for
relatively small fold differences. On the other hand, our ear-
lier studies suggested the presence of inter-strain differences
in the level of mRNA variants for the number of genes (for
example, Atp1a2 and Comt) [14]. The results obtained here
extend our previous observations and present a broader list of
potential candidate genes for further study. The influence of
differences in particular genes on the genome-phenome
interaction remains to be elucidated.
In the present study, we analyzed the effects of acute and
chronic morphine treatment. Genotype-independent influ-
ences of morphine treatment on gene expression profile in the
striatum were evaluated in all four mouse strains. The degree
of alteration in gene expression (618 transcripts) was signifi-
cantly less than the above-mentioned differences between the
strains in terms of basal transcript levels.
Acute morphine injection increased the mRNA level of a large
group of genes, including the functional groups of transcripts
associated with response to abiotic and temperature stimuli.
These transcriptional responses are potentially related to
common physiologic effects induced by opioids in mice [10].
Both acute and chronic morphine administration resulted in
mRNA upregulation of genes classified using GO terms as fac-
t o r s  i n v o l v e d  i n  t h e  r e g u l a t i o n  o f  c e l l u l a r  p r o c e s s e s  a n d
apoptosis, whereas mRNA abundance of genes linked to nerv-
ous system development and cell-cell communication
decreased. However, we consider GO analysis as providing an
indication of functional association between groups of genes,
rather demonstrating a direct connection with each process
described by a GO term. For instance, serum/glucocorticoid-
regulated kinase 3 (Sgk3) was classified as a gene associated
with apoptosis, whereas the expression of Sgk3 in brain was
also associated with memory consolidation [20]. Our data
include changes in the expression of genes with functional
importance to the prolonged effects of morphine, such as
plasminogen activator (Plat) and FK506-binding protein 5
(Fkbp5). Morphine upregulation of Plat mRNA was linked to
drug-related reward properties [21], whereas the inhibition of
Fkbp5 was found to prevent symptoms of opioid withdrawal
syndrome [22]. In our experiments, morphine-induced
changes in striatal gene expression of components of intracel-
lular signaling pathways, for example calcium/calmodulin-
dependent protein kinase I γ (Camk1g) and the receptor for
Wnt signaling proteins frizzled homolog 2 (Fzd2), were iden-
tified. However, the previously described downregulation of
mRNAs for cytoskeleton-related genes and genes involved in
mitochondrial respiration after acute morphine was not
confirmed [23]. These discrepancies may result from the
experiments being conducted at different time points.
In comparison with acute morphine, repeated administration
caused a large decrease in mRNA levels of many genes,
including the over-represented group of histone transcripts
involved in nucleosome assembly and chromatin remodeling.
However, remodeling of chromatin was identified as impor-
tant regulatory mechanism of cocaine-induced plasticity in
striatum [24]. Moreover, one of the genes with decreased
mRNA level after repeated morphine treatment, namely oli-
godendrocyte transcription factor 2 (Olig2), was identified as
an essential transcriptional regulator in neuron and oli-
godendrocyte specification [25] and was recently postulated
to be involved in susceptibility to schizophrenia [26]. In sum-
mary, these observations may suggest that chronic morphine-
Modulation of behavioral response to morphine by RU486 pretreatment Figure 6
Modulation of behavioral response to morphine by RU486 pretreatment. 
(a) Effects of acute morphine administration (20 mg/kg, subcutaneously) 
on locomotor activity were analyzed in glucocorticoid antagonist-treated 
C57BL/6J mice. Mice were injected with 20 mg/kg RU486 (RU20). After 30 
min, the mice were injected with morphine (Mor) or saline (Sal). Column 
bars correspond to the mean number of photocell counts per group with 
standard error (n = 6 to 8) collected from 0 to 180 min after 
administration of morphine. (b) Influence of glucocorticoid receptor 
antagonist pretreatment on the development of opioid physical 
dependence was analyzed in C57BL/6J mice. RU486 (20 mg/kg) was 
administered 30 min before acute injection of morphine (100 mg/kg, 
subcutaneously). The next day animals were injected with an additional 
dose of morphine (20 mg/kg, subcutaneously) following by the injection of 
naloxone (15 mg/kg, subcutaneously). The level of morphine dependence 
is presented as mean naloxone-precipitated withdrawal jumping response 
(number of jumps per 30 min after naloxone injection) with standard 
error (n = 5 to 6). Control animals were treated with vehicle (Veh) and 
saline (Sal). The data presented in panels a and b were analyzed using 
analysis of variance following Tukey's post hoc test (*P < 0.05; ns, not 
significant).
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induced alterations in the striatum are related to cell plastic-
ity and structural changes.
One of the main aims of the present study was to investigate
genotype-dependent differences in transcriptional response
induced by morphine. Comparison of the number of genes
regulated by morphine across the four strains has indicated
that acute response is markedly greater in DBA/2J and SWR/
J mice than in C57BL/6J and 129P3/J mice. DBA/2J and
SWR/J strains exhibited over-representation of metabolism-
related genes across the list of regulated transcripts. Both
strains exhibited greater hypothermic response to single mor-
phine administration [10]. Furthermore, acute morphine
induces increase in locomotor activation in C57BL/6J and
129P3/J mice, but not in DBA/2J and SWR/J [10]. The find-
ings suggest that strain differences in over-expression of
metabolism-related genes may be associated with behavioral
responses to morphine. These changes in gene expression
might be among the possible factors that determine develop-
ment of morphine-related traits. For instance, DBA/2J and
SWR/J strains exhibited low morphine preference, measured
as oral self-administration of morphine [12].
The obtained profiles of gene expression indicate that some of
the alterations in transcription appear to be related to the
physiologic state of the whole body. Co-expression of three
genes that are typically associated with cellular stress and
temperature stimulus (Hspa1a, Haspa1b, and Dnajb1) was
detected after morphine treatment. Further analysis of heat
shock protein 1b gene expression revealed inter-strain differ-
ences in response. The greatest induction of heat shock pro-
tein (HSP) mRNAs after acute morphine administration was
observed in DBA/2J, whereas after chronic morphine treat-
ment it was observed in C57BL/6J mice. As mentioned above,
acute morphine produces severe hypothermia in mice [10].
However, the inter-strain differences in profile of HSP mRNA
expression after acute morphine were negatively related to
changes in body temperature. On the other hand, opioid-
induced hypoxia caused by respiratory depression with differ-
ent escalation in the strains might be involved in expression
of HSP genes. Increased expression of Hsp70 mRNA in rat
brain was suggested to be a protective mechanism against the
harmful effects of opiates [27]. Interestingly, different
responses in gene expression of Hsp70 were observed
between rats after active and passive morphine administra-
tion [28]. The presented results support previous data and
implicate regulation of HSP gene expression as a potential
marker of physiologic alterations of homeostatic processes
induced by morphine in brain.
To identify transcriptional response associated with specific
opioid-related traits, changes in mRNA level were correlated
with morphine-induced behavioral traits (Additional data file
5). Severe symptoms of opioid withdrawal observed in SWR/
J mice were associated with strong transcriptional activation
of cytotoxic T lymphocyte-associated protein 2 (Ctla2a) and
methionine adenosyltransferase II (Mat2a) genes after acute
administration of morphine, whereas changes in gene expres-
sion of adenosine A2a receptor (Adora2a) were negatively
related to the level of morphine physical dependence across
the four inbred mouse strains (Figure 7). A role of functional
activation of the adenosine A2a receptor in opioid withdrawal
was previously reported [29].
Decreased expression of several genes linked to the transmis-
sion of nerve impulse after chronic treatment may be con-
nected with the development of tolerance to effects of opioids
observed in C57BL/6J strain, including morphine-responsive
genes encoding NPY receptor (Npy5r) and GABAa receptor
subunit (Gabrg1). A moderate transcriptional response to
acute treatment and a large decrease in the mRNA abundance
of many genes after chronic morphine in C57BL/6J occur
together with an enhanced preference [30] for and intake of
morphine in this strain [12]. Increased mRNA abundance of
TSC22 domain family 3 (Tsc22d3) and zinc finger and BTB
domain containing 16 (Zbtb16) transcripts was found to be
positively related to morphine preference (Figure 7).
Strain differences in response to acute morphine were also
detected in the level of nuclear factor of kappa light chain
gene enhancer in B-cells inhibitor α (Nfkbia) mRNA. Signifi-
cant induction of Nfkbia gene expression after 4 hours was
detected in C57BL/6J mice. A similar profile of gene
transcription was observed for Tsc22d3. It is well established
that gene transcription of Nfkbia as well as Tsc22d3 can be
mediated by GR and controlled by the level of glucocorticoids
[17,31]. Nuclear receptor GR is a ligand-activated transcrip-
tion factor that directly modulates transcription of down-
stream genes [32]. Therefore, it has been suggested that
glucocorticoids are potentially factors that are responsible for
the detected increase in expression of these genes. Further-
more, we have identified a relatively large group of genes with
parallel expression profiles to that of Tsc22d3 (Sgk, Klf15,
Fzd2, Gpt2, Rhpn2, Nt5e, and Nfkbia), which may indicate
morphine-induced co-regulation of these genes.
Therefore, the putative involvement of glucocorticoids in the
modulation of transcription of these genes was further stud-
ied using the GR antagonist RU486. Prior administration of
RU486 blocked morphine-produced induction of Tsc22d3,
Zbtb16, and Nfkbia mRNAs. The functional consequences of
this transcriptional process remain unknown. However, it
was previously shown that GR-dependent transmission influ-
ences the behavioral response to morphine in rats [33,34].
The present study demonstrated that GR blockade can inhibit
an increase in locomotor activity following morphine admin-
istration in C57BL/6J mice. Influence of the GR antagonist on
the relatively fast stimulatory effect of morphine on locomo-
tion may suggest the involvement of a nongenomic mecha-
nism. Nevertheless, several lines of evidence indicate the GRs
also play an important role in the development of opioid-
related phenotype. Secretion of glucocorticoids is involved inR128.12 Genome Biology 2007,     Volume 8, Issue 6, Article R128       Korostynski et al. http://genomebiology.com/2007/8/6/R128
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sensitization to activatory effects of morphine [35]. On the
other hand, substantial attenuation of the morphine analgesic
tolerance after administration of RU486 has been reported in
rats [36]. Furthermore, our findings indicated involvement of
GRs in the development of morphine physical dependence.
Thus, the GR antagonist appears to modify both the behavio-
ral and transcriptional responses to morphine. Therefore,
GR-mediated gene expression in the striatum may play a role
in the chronic effects of morphine and could be involved in
the formation of drug-associated behavior. This hypothesis is
also supported by the recent findings that GRs in the nucleus
accumbens are necessary for the development of conditional
place preference for morphine [37]. The increase in glucocor-
ticoid levels induced by acute stress facilitates the consolida-
Morphine-induced changes in gene expression correlated with the behavioral response Figure 7
Morphine-induced changes in gene expression correlated with the behavioral response. Transcriptional and behavioral responses to morphine were 
compared across the four inbred strains of mice with specific opioid-related phenotype (C57BL/6J, DBA/2J, 129P3/J, and SWR/J). Behavioral data were 
gathered as described in the Materials and methods section. The results were obtained by using Pearson correlation (Additional data file 5). Correlation 
between each opioid-related trait and transcriptional response to acute morphine is presented on the left panel along with chronic morphine on the right 
panel. Positive correlations between changes in gene expression and behavioral response are highlighted by red color (+), and negative ones are 
highlighted by the blue color (-).http://genomebiology.com/2007/8/6/R128 Genome Biology 2007,     Volume 8, Issue 6, Article R128       Korostynski et al. R128.13
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tion of memories associated with emotional stimuli [38]. The
greatest induction of the genes putatively regulated by gluco-
corticoids was detected in C57BL/6J mice, an inbred strain
characterized by high preference for morphine as well as alco-
hol [12,39].
It is likely that induction of glucocorticoids and further GR-
dependent gene expression might also enhance learning of
drug-related stimuli. It was suggested that serum-glucocorti-
coid-inducible kinase (Sgk) is involved in memory consolida-
tion of hippocampus-dependent learning [40]. Also,
implication of the Nfkbia regulatory protein of nuclear factor-
κB in memory formation in mice has already been proposed
[41]. Withdrawal from chronic morphine treatment induced
changes in the mRNA abundance of Sgk and Nfkbia in rat
prefrontal cortex [42] and mouse locus coeruleus [22]. Fur-
thermore, alterations in expression of Sgk and Nfkbia were
also observed after acute administration of ethanol [43-45].
However, shared transcriptional regulation of the genes men-
tioned here was not emphasized or directly associated with
the action of glucocorticoids. The potential therapeutic use of
GR antagonists in treatment for drug abuse was previously
suggested [46]. The present study identified a group of GR-
dependent genes that are regulated in response to morphine.
Moreover, our results provide new insights into the
morphine-induced mechanism of action of glucocorticoids in
the brain.
Conclusion
Comparison of morphine-induced changes in striatal gene
expression across the four inbred mouse strains indicated
new biologic mechanisms that are potentially involved in the
action of morphine. The results describe strain differences in
the magnitude of transcriptional response to acute treatment
and in the degree of tolerance in gene expression observed
after chronic morphine administration. Further profiling of
gene expression and transcriptional activity are required to
characterize fully the mechanisms of transcriptional regula-
tion and the dynamics of changes in mRNA abundance
induced by opioids in mice. As a final point, the obtained
results indicated the participation of several novel molecular
factors in the effects of morphine and suggested a transcrip-
tional basis for the well known association between glucocor-
ticoids and opioid addiction.
Materials and methods
Mice
Adult male (8 to 10 weeks old) 129P3/J (000690), DBA/2J
(000671), C57BL/6J (000664), and SWR/J (000689) mice
(Jackson Laboratory, Bar Harbor, ME, USA) were housed six
per cage, under a 12 hour dark/light cycle, with free access to
food and water. Animals weighing 20 to 30 g were used
throughout the experiments. The animal protocols used in
the study were approved by the local Bioethics Commission at
the Institute of Pharmacology, Polish Academy of Sciences
(Krakow, Poland).
Morphine treatment
Morphine (morphine hydrochloride; Polfa, Kutno, Poland)
was administered subcutaneously. Experimental groups
(control, and acute and chronic morphine) consisted of nine
animals from each strain. To obtain the most reliable
comparison, control and acute morphine groups received
injections of saline for 4 days at the same time schedule as the
chronic group received morphine (Figure 1). On day 5, acutely
treated animals were injected with a single dose of morphine
and killed by decapitation after 4 hours. Chronically treated
animals were injected with increasing doses of morphine for
5 days. Mice received morphine thrice daily (09:00 hours,
13:00 hours, and 17:00 hours) for 4 days using a dosing
schedule of 10, 20, 40, and 40 mg/kg morphine on days 1, 2,
3, and 4, respectively. On the last day, a final morphine dose
of 40 mg/kg was administered, and 4 hours after the last
injection the animals were killed. Mice in control groups were
killed 4 hours after the last injection of saline. The dose
scheme and time schedule were used in order to maximize
strain differences in response to morphine [10,13,47].
RU486 treatment
Five groups of six C57BL/6J mice were used in the gene
expression experiment with morphine and RU486 (Sigma-
Aldrich, St. Louis, MO, USA) treatment. The control group
was injected subcutaneously with saline and intraperitoneally
with 20% (2-Hydroxypryl)-β-cyclodextrine (vehicle for
RU486; Sigma). RU486 (20 or 40 mg/kg in vehicle, intraperi-
toneally) was administered 30 min before morphine adminis-
tration (20 mg/kg, subcutaneously). The doses of RU486
were selected based on a previous report that showed the
effects of peripheral administration on the central nervous
system [48]. For the qPCR experiment, animals were killed 4
hours after the morphine or saline injection.
Behavioral testing
An independent pool of C57BL/6J mice was used in the
behavioral experiments (five to eight animals per experimen-
tal group). In the locomotor activity test mice were
individually placed in the center of a test cage containing pho-
tocells (20 cm × 10 cm × 12 cm). The photocells recorded the
number of beam interruptions in the horizontal plane every
15 min over a 4.5 hour period. After 1 hour, the mice were
injected with RU486 (20 mg/kg in vehicle, subcutaneously).
The control group was injected with saline and vehicle. The
influence of RU486 (20 mg/kg in vehicle, subcutaneously) on
basal locomotor activity was also evaluated. After 30 min,
mice were injected with saline or morphine (20 mg/kg, sub-
cutaneously). Measurement of locomotor activity was per-
formed for the next 3 hours. The results were calculated as an
area under curve.R128.14 Genome Biology 2007,     Volume 8, Issue 6, Article R128       Korostynski et al. http://genomebiology.com/2007/8/6/R128
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Physical dependence was induced by acute injections of mor-
phine (100 mg/kg, subcutaneously). A single RU486 dose (20
mg/kg in vehicle, subcutaneously) was administered 30 min
before the injection of morphine. On the second day mice
received an additional subcutaneous dose of 20 mg/kg mor-
phine, followed by a single naloxone dose (15 mg/kg, subcu-
taneously) 3 hours later. Mice did not receive RU486 on the
day of the test. For mice in control groups, saline was substi-
tuted for morphine. Measurement of naloxone-precipitated
withdrawal was performed as described in previous studies
[13]. Mean jump frequency per 15 min was used as the meas-
ure of dependence. Behavioral data was analyzed by two-way
analysis of variance (ANOVA) followed by Bonferroni post
hoc test, with RU486 treatment and morphine treatment as
the main factors.
Tissue collection and RNA isolation
After decapitation, brains were removed from the skulls and
dissected rapidly. Samples containing the rostral part of cau-
date/putamen plus the nucleus accumbens (referred to as the
striatum) were collected. The samples were placed in individ-
ual tubes with the tissue storage reagent RNA later (Qiagen
Inc., Valencia, CA, USA), frozen on dry ice, and stored at -
70°C until RNA isolation. Samples were thawed at room tem-
perature and homogenized in 1 ml Trizol reagent (Invitrogen,
Carlsbad, CA, USA). RNA isolation was performed in accord-
ance with the manufacturer's protocol. Quality of the total
RNA was assessed by the intensity of 28S and 18S bands after
denaturating agarose electrophoresis with SybrGold staining
(Molecular Probes, Inc., Eugene, OR, USA) and by the
spectrophotometric ratio A260/A280 (1.9 to 2.1). RNA con-
centration was measured using the fluorescent reagent
RiboGreen (Molecular Probes, Inc.).
Microarray hybridization
Total RNA from three animals was pooled and further puri-
fied using the RNeasy Mini Kit (Qiagen Inc.). The quality of
RNA was additionally determined by chip-based capillary
electrophoresis using RNA 6000 Nano LabChip Kit and
Agilent Bioanalyzer 2100 (Agilent, Palo Alto, CA, USA), and
there was little evidence of degradation products in any of the
total RNA samples. For each array, independent pools of RNA
from three animals were prepared. Preparation of cRNA was
performed according to the protocol provided by Affymetrix
(Santa Clara, CA, USA). Total RNA (5 μg) derived from each
pool was converted to double-stranded cDNA using the
SuperScript System (Invitrogen) and an oligo(dT24) primer
containing a T7 RNA polymerase promoter site (Genset Oli-
gos, La Jolla, CA, USA). Biotin-labeled cRNA was synthesized
from cDNA using a BioArray High Yield RNA Transcript
labelling Kit (ENZO, Diagnostics, Farmingdale, NY, USA) and
purified using a GeneChip Cleanup Sample Module (Qiagen
Inc.). The yield of the in vitro transcription reaction was
determined by product absorbance at 260 nm measured
using NanoDrop ND-1000 (NanoDrop Technologies, Inc.,
Montchanin, DE, USA), and the size of cRNA probes was eval-
uated by using the RNA 6000 Nano LabChip Kit (Agilent).
Following labeling, samples were hybridized to the GeneChip
Test3 array (Affymetrix) for quality control. Fragmented
cRNA (15 μg) was used for hybridization to the GeneChip
Mouse Genome 430 2.0 arrays (Affymetrix). Arrays were
washed and stained with streptavidin-phycoerythrin (Merck,
Darmstadt, Germany) in Fluidic Station 400 (Affymetrix), in
accordance with the standard protocol of the manufacturer.
The arrays were scanned using the GeneChip Scanner 3000
(Affymetrix). Three biologic replicates of the microarrays
were prepared per experimental group of animals for a total
of 36 arrays.
Microarray quality control and normalization
The expression data were processed using the GeneChip
Operating Software (Affymetrix) to generate MAS5 CEL files.
Chip quality was assessed using R 2.3.0 with the simpleaffy
package [49,50]. Quality control data for all 36 microarray
runs in the experiment were obtained using the MAS5 algo-
rithm. The mean 3'/5' degradation ratio for control probe sets
of housekeeping genes was measured: Gapdh (AFFX-Gapdh-
Mur/M32599) -0.2 (-0.39> ... <0.57) and Actb (AFFX-b-Act-
inMur/M12481) 0.57 (0.33> ... <1.24). Array normalization
resulted in a mean scaling factor of 0.87 (± 0.57). The mean
percentage of the present call was 51.34 (47.3> ... <54.63),
and the mean intensity of the average background ranged
from 27.9 to 76.9. Arrays determined to be acceptable were
further analyzed to identify genes with altered expression pat-
terns. Data was normalized using three different methods
using RMAExpress 0.4.1 (RMA), dChip 2006 (MBEI), and
PerfectMatch 2.3.3 (PDNN) software [51-53]. Quantile nor-
malization was performed using RMA, PDNN, and MBEI
algorithms. A model-based expression index was calculated
using perfect match/mismatch (PM/MM) method. Multiple
a n a l y s i s  s t r a t e g i e s  w e r e  u s e d  t o  i d e n t i f y  t h e  m o s t  r o b u s t
changes in gene expression.
Gene filtering and ranking
To remove genes that are regarded as not expressed in the
analyzed brain tissue, probe sets with hybridization signals
close to the background level were filtered out. The following
criteria were applied for probe set detection: present call at
least in 25% of PM/MM pairs and signal intensity greater
than 6.64 (log2 data) in at least 25% of arrays, both measured
using the MBEI algorithm. Statistical analysis was performed
on the list of detected probe sets. Significance levels (P values)
of differences between the groups were calculated for each
probe set using a MANOVA for each of three pre-processing
methods. Correction for multiple testing was applied sepa-
rately for each of the main factors from MANOVA by control-
ling percentage FDR. The FDR was computed using the
p.adjust function in R software [54]. Gene ranking was based
on FDR levels of three selected normalization methods. A
probe set scored 1, 2, or 3 points if it achieved cut-off at P <http://genomebiology.com/2007/8/6/R128 Genome Biology 2007,     Volume 8, Issue 6, Article R128       Korostynski et al. R128.15
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0.01, P < 0.001, or P < 0.0001, respectively, for each of the
three methods. Two criteria for threshold point were used:
the first produced a list of probe sets with rank greater than 3
(P < 0.01 in all the three normalization methods) and the sec-
ond list with rank greater than 7 (P < 0.0001 in two of the
methods and at least 0.001 in the third). An applied approach
that takes into account the level of agreement between the
three methods of normalization was previously established
[14].
To assess the contribution of strain and morphine treatment
effects, we performed multiple regression analysis of expres-
sion values, with strain and treatment as main effect predic-
tors using the lm function in R. Contributions of the effects
were determined for each gene separately.
Hierarchical clustering was performed with dChip software
using Euclidean distance and average linkage method. Rela-
tive expression levels and fold change measures were com-
puted from MBEI PM/MM data. To simplify the description
of microarray data, results from each probe set were assumed
to be the level of mRNA abundance of the transcript. Probe
sets on the Affymetrix microarray were designed to detect
specific transcripts and are adequately annotated. However,
it must be noted that for some probe sets this assumption may
not be fulfilled. Therefore, every list of probe sets obtained in
the analyses is included in Additional data files. Direct probe
mapping against publicly available mRNAs/cDNA sequences
was done by using mouse BLAT tool for the UCSC genome
browser [55].
Gene Ontology analysis
The functional annotation analysis tool DAVID 2006 was
used to identify over-represented ontologic groups among the
gene expression profiles and to group genes into functional
classifications [56]. The list of 21,467 detected probe sets was
uploaded as a background list. Over-represented GO terms
(GOTERM_ALL level) were defined as having at least three
transcripts and P = 0.01, under Fisher's exact test.
Correlation between genomic and behavioral response 
to morphine
Relationships between the transcriptional response to mor-
phine and opioid-related traits were studied using correlation
analysis. Gene expression results were compared with the
previously published behavioral data for the four inbred
mouse strains. The first line of evidence demonstrated open
field locomotor activity in response to acute morphine (16
mg/kg), measured from 0 to 30 min after injection, and com-
pared with a saline control group (C57BL/6J = 4,116, 129P3/
J = 5,880, SWR/J = -1,500, and DBA/2J = -3,088); this was
reported by Belknap and coworkers [10]. Second, morphine
tolerance has been demonstrated, calculated as a shift in mor-
phine analgesic potency after chronic treatment (C57BL/6J =
7.2, SWR/J = 5, DBA/2J = 2.9, and 129P3/J = 0.8); this was
reported by Kest and colleagues [47]. Third, physical depend-
ence on morphine has been demonstrated following chronic
treatment, as indicated by a naloxone precipitated with-
drawal jumping response (SWR/J = 204 jumps/15 min,
C57BL/6J = 68 jumps/15 min, DBA/2J = 45 jumps/15 min,
and 129P3/J = 7 jumps/15 min); these data were reported by
Kest and coworkers [13]. The fourth line of evidence demon-
strated voluntary morphine consumption in two-bottle
choice paradigm (C57BL/6J = 134 mg/kg per day, 129P3/J =
24 mg/kg per day, DBA/2J = 15 mg/kg per day, and SWR/J =
6 mg/kg per day); these ata were reported by Belknap and
colleagues 1993 [12]. The expression level of genes altered by
acute and/or chronic morphine (699 probe sets, obtained by
MBEI PM/MM) and behavioral data were normalized using
z-score transformation. Associations were computed using
the Pearson's correlation. Input data, annotations for probe
sets, and the obtained results are included in Additional data
file 5.
Identification of genes co-expressed in response to 
morphine
Genes with related patterns of expression were selected from
the list of probe sets with significant changes after morphine
treatment. To confirm associations between the transcripts,
additional analysis was performed on an independent set of
data. The WebQTL database was used to assemble transcripts
into groups with potentially common regulatory mechanisms
[16]. A hippocampus gene expression dataset with results
from 86 BXD RI strains (Hippocampus Consortium M430v2
Dec05 PDNN) was applied as an easily accessible tool with
relatively high ability to detect associations between genes.
Selected probe sets for genes regulated by morphine were
analyzed using the trait correlation WebQTL tool. Correla-
tions were computed using Pearson's product-moment. The
most significant top 200 results were obtained. Only probe
sets with positive correlations (r > 0.6) were extracted and
used in further analyses. A list of probe sets with significant
changes after morphine and positive correlation across the
BXD RI panel was generated. Network graphs were obtained
with WebQTL interface using Pearson's product-moment and
default parameters.
Real-time PCR
Reverse transcription was performed using Omniscript
reverse transcriptase (Qiagen Inc.) at 37°C for 60 min. qPCR
reactions were performed using Assay-On-Demand Taqman
probes (Additional data file 4), in accordance with the manu-
facturer's protocol (Applied Biosystems) and run on the iCy-
cler device (BioRad) with the 3.0a software version. RT
reactions were carried out in the presence of RNase inhibitor
(rRNAsin; Promega, Madison, WI, USA) and oligo(dT16)
primer (Qiagen Inc.). cDNAs were diluted 1:6 with H2O and
for each reaction about 50 ng of cDNA synthesized from total
RNA template from individual animals was used. To reduce
the contribution of contaminating genomic DNA, primers
were designed to span exon junctions. In addition, for each
assay, control reactions without RT enzyme were performed.R128.16 Genome Biology 2007,     Volume 8, Issue 6, Article R128       Korostynski et al. http://genomebiology.com/2007/8/6/R128
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Amplification efficiency for each assay was determined by
running a standard dilution curve. Expression of hypoxan-
thine guanine phosphoribosyl transferase 1 (Hprt1) tran-
script with a stable level between the strains and after the
treatment was quantified to control for variation in cDNA
amounts. The cycle threshold values were calculated auto-
matically by iCycler IQ 3.0a software with default parameters.
Abundance of RNA was calculated as 2-(thresholdcycle). Data
were analyzed by two-way ANOVA followed by Bonferroni
post hoc test.
Additional data files
The following additional data are available with the online
version of this manuscript. Additional data file 1 is a table list-
ing the results of two-way ANOVA (FDR < 1%). Additional
data file 2 contains lists of probe sets of genes with expression
altered by acute and chronic morphine (ANOVA; FDR < 1%).
Additional data file 3 is a table listing the results of the GO
analysis. Additional data file 4 contains the results of valida-
tion of microarray data obtained using the qPCR method.
Additional data file 5 lists the complete results of correlation
analysis between the transcriptional response to morphine
and opioid-related traits (see Materials and methods).
Additional data file 1 Results of two-way ANOVA (FDR < 1%) Lists of probe sets and gene names altered by strain (3457) and  morphine treatment (661) as well as with significant interaction  (48) are available as separate sheets. List of transcripts with differ- ences in both the factors (178) was also included. In addition, genes  reported in previous gene expression studies on morphine action in  a brain are indicated. Click here for file Additional data file 2 Probe sets of genes with expression altered by acute and chronic  morphine (ANOVA, FDR < 1%) The results were obtained using fold change (>1.2) of gene expres- sion level compared with the saline control group. Effects of mor- phine treatment were analyzed in all of the strains as well as  separately in each of them. Numbers of probe sets correspond to  those in Table 2. Click here for file Additional data file 3 Results of the Gene Ontology analysis Presented are significant functional categories (GO terms)  enriched with genes regulated in response to acute and/or chronic  morphine, along with lists of probe sets and gene names classified  to each GO category. Click here for file Additional data file 4 Results of validation of microarray data obtained using qPCR  method Results for selected genes are presented as mean (± standard error)  compared with the saline control group. List of Taqman assays  used in qPCR experiments with ID and exon boundaries is  included. Click here for file Additional data file 5 Complete results of correlation analysis between the transcrip- tional response to morphine and opioid-related traits The expression level (MBEI PM/MM algorithm) of genes altered by  acute and/or chronic morphine (699 probe sets) and behavioral  data were normalized using z-score transformation. Associations  were computed using the Pearson's correlation. Click here for file
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